HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase1/-2 study of Pomalidomide in myelofibrosis.

AuthorsRuben A Mesa, Animesh D Pardanani, Kebede Hussein, Wenting Wu, Susan Schwager, Mark R Litzow, William J Hogan, Ayalew Tefferi
JournalAmerican journal of hematology (Am J Hematol) Vol. 85 Issue 2 Pg. 129-30 (Feb 2010) ISSN: 1096-8652 [Electronic] United States
PMID20052748 (Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Letter)
Chemical References
  • Anti-Inflammatory Agents
  • Immunosuppressive Agents
  • Thalidomide
  • Prednisolone
  • pomalidomide
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Anemia (drug therapy, etiology, pathology)
  • Anti-Inflammatory Agents (administration & dosage)
  • Female
  • Humans
  • Immunosuppressive Agents (administration & dosage)
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Prednisolone (administration & dosage)
  • Primary Myelofibrosis (complications, drug therapy, pathology)
  • Thalidomide (administration & dosage, analogs & derivatives)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: